Compare Globus Medical Inc. Class A Common Stock (GMED) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs SYSCO Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while SYSCO Corporation trades at $80.81 (market cap $38.88B). The key difference: SYSCO Corporation is far larger — about 3.8× Globus Medical Inc. Class A Common Stock's market cap, and SYSCO Corporation pays a 2.78% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and SYSCO Corporation for 78 Days on average.
| GMED | SYY | |
|---|---|---|
Market Cap | $10.25B | $38.88B |
Volume | 1,108,124 | 2,477,462 |
Sector | Health | Consumer Staples |
52-Week High | $96.82 | $91.16 |
52-Week Low | $58.33 | $69.30 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $9.76B | $52.06B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SYY trades at $80.97, up 2.88% with a bearish technical signal despite recent earnings beats. The company maintains steady revenue growth, reaching $81.37B in 2025, with strong profitability metrics including 78.16% ROE. Recent developments include a $500M AI efficiency program and a $1.5B senior notes offering. Analyst consensus remains positive with 60% buy ratings and an $85.75 price target, though technical indicators show resistance near $79-80 levels.
SYY presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 0.45 P/S ratio and dividend yield, supported by consistent revenue growth and AI-driven efficiency initiatives. Key risks include high debt levels at 49.75% debt-to-asset ratio and margin pressure as net income margin declined to 2.08%. Institutional ownership trends positive with recent pension fund increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
